Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Title
Intervention Indication Therapeutic Area Year Actions
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation Carboplatin (Paraplatin) , Cisplatin (Platinol) , Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) - first line Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Nivolumab with ipilimumab for previously untreated locally advanced non-small-cell lung cancer Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Nivolumab with chemotherapy neoadjuvant followed by nivolumab adjuvant for treating early stage non-small-cell lung cancer Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Nivolumab in combination with ipilimumab in addition to chemotherapy for treating non-small cell lung cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Nivolumab in combination with ipilimumab for malignant pleural mesothelioma – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Malignant pleural mesothelioma (MPM) Lung and Respiratory Cancer 2019 View  |  Download
Nivolumab in combination with ipilimumab for early stage non-small cell lung cancer -neoadjuvant Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Nivolumab for adjuvant treatment of stage IB-IIIA non-small cell lung cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Nivolumab (Opdivo) in combination with platinum Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
1 2 4 5 6 7 8 11 12
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications